Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528497 | 1.00 | KDM4E (0.31) | KDM4EMEN1KMT2AMAP1LC3B | |
| SCHEMBL827273 | 1.00 | KDM4E (0.31) | KDM4EMEN1KMT2AMAP1LC3B | |
| SCHEMBL710471 | 0.84 | SMARCA4 (0.31) | KDM4E | |
| SCHEMBL21990761 | 0.84 | SMARCA4 (0.33) | KDM4E | |
| SCHEMBL710472 | 0.84 | SMARCA4 (0.31) | KDM4E | |
| SCHEMBL17893716 | 0.84 | SMARCA4 (0.31) | KDM4E | |
| SCHEMBL28152878 | 0.84 | SMARCA4 (0.33) | KDM4E | |
| SCHEMBL4696208 | 0.83 | MAP1LC3B (0.41) | KDM4EMEN1KMT2AMAP1LC3B | |
| SCHEMBL19358589 | 0.80 | — | — | |
| SCHEMBL827122 | 0.77 | USP2 (0.38) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3159344-B1 | AMINO PYRANOID RING DERIVATIVE AND COMPOSITION AND USE THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO LTD (CN) | 2023-09-20 | — | — | EP | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220185813-A1 | MODULATORS OF AMPA RECEPTOR SIGNALING | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2022-06-16 | — | — | US | disclosed |
| EP-3935059-A1 | MODULATORS OF AMPA RECEPTOR SIGNALING | Centre For Addiction And Mental Health (CA) | 2022-01-12 | — | — | EP | disclosed |
| WO-2021032323-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10065962-B2 | Amino pryan ring derivative and composition and use thereof | SICHUAN HAISCO PHARMACEUTICAL CO., LTD (CN) | 2018-09-04 | — | — | US | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017081590-A1 | PROCESS FOR THE PREPARATION OF OMARIGLIPTIN | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2017-05-18 | — | — | WO | disclosed |
| US-20100234403-A1 | Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK & CO., INC. | 2010-09-16 | — | — | US | disclosed |
| EP-2190428-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| US-7678905-B2 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20090105284-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV for the Treatment or Prevention of Diabetes | MERCK & CO., INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009025784-A1 | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009014676-A1 | NOVEL CRYSTALLINE FORM OF A DIHYDROCHLORIDE SALT OF A DIPEPTIDYL PEPTIDASE-IV INHIBITOR | MERCK & CO., INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| EP-1888066-A2 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck and Co., Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070232676-A1 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2007-10-04 | — | — | US | disclosed |
| WO-2006127530-A2 | AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120863-A1 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | DPP4, DPP3, DPP7 | KDM4E 1248/4885MEN1 4301/4885KMT2A 3176/4885 |
| US-20090105284-A1 | Aminocyclohexanes as Dipeptidyl Peptidase-IV for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | KDM4E 753/4885MEN1 4381/4885KMT2A 2897/4885 |
| US-10065962-B2 | Amino pryan ring derivative and composition and use thereof | DPP4, DPP8, DPP3 | KDM4E 642/4885MEN1 2883/4885KMT2A 2447/4885 |
| US-20070232676-A1 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | KDM4E 1248/4885MEN1 4301/4885KMT2A 3176/4885 |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | KDM4E 576/4885MEN1 3166/4885KMT2A 1040/4885 |
| US-20220185813-A1 | MODULATORS OF AMPA RECEPTOR SIGNALING | GRM2, GRM1, GRIK2 | KDM4E 3397/4885MEN1 4699/4885KMT2A 2796/4885 |
| US-20100234403-A1 | Aminotetrahydropyrans as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | KDM4E 1248/4885MEN1 4301/4885KMT2A 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.